ClinicalTrials.gg
Not yet recruitingNCT07856667COINCIDEUpdated Nov 19, 2026

COINCIDE: Cardineurovascular dIsease and Obstructive Airway Disease

An observational study in Chronic Obstructive Pulmonary Disease (COPD), Severe Asthma and Cardiovascular Diseases, sponsored by VASCage GmbH. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by VASCage GmbH · Observational

How we know

Updated Nov 19, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Study summary

Patients with chronic obstructive pulmonary disease (COPD) and severe asthma frequently present with cardiovascular comorbidities that contribute substantially to morbidity and mortality. Early identification and appropriate management of cardiovascular disease are increasingly recognized as important components of comprehensive care for patients with obstructive airway diseases.

The COINCIDE study is a prospective longitudinal observational cohort study conducted at the Department of Pulmonology, Medical University of Innsbruck. The study aims to systematically document cardiovascular comorbidities in patients with COPD and severe asthma and to evaluate their association with disease progression, therapeutic management, exacerbation rates, symptom burden, and pulmonary function over time.

Clinical, functional, laboratory, and imaging data obtained as part of routine clinical care will be collected prospectively during two study visits separated by approximately 24 months. Up to 350 adult participants will be enrolled and followed over a period of five years.

Read the detailed description

Cardiovascular comorbidities are among the major determinants of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD) and severe asthma. Despite guideline recommendations, systematic assessment and management of cardiovascular disease in these patient populations remain heterogeneous in routine clinical practice.

The primary objective of the COINCIDE study is to characterize the prevalence and spectrum of cardiovascular comorbidities in adult patients with COPD or severe asthma treated at a tertiary pulmonary outpatient clinic. Furthermore, the study aims to evaluate the relationship between cardiovascular comorbidities and clinical outcomes, including exacerbation frequency, symptom burden, pulmonary function, and treatment strategies.

This is a single-center, prospective, longitudinal observational cohort study conducted at the Department of Pulmonology, Department of Internal Medicine II, Medical University of Innsbruck, Austria. Clinical, functional, laboratory, and imaging findings obtained during routine care will be collected in a structured manner and analyzed longitudinally.

Participants will undergo study assessments at baseline and after approximately 24 months. The study is planned to enroll up to 350 adult patients and will be conducted over five years.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Severe Asthma
  • Cardiovascular Diseases

Keywords

  • COPD
  • Chronic Obstructive Pulmonary Disease
  • Severe Asthma
  • Cardiovascular Comorbidity
  • Cardiovascular Disease
  • Pulmonology
  • Cohort Study
  • Longitudinal Study
  • Real World Data
03

In context

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

This study's planned enrollment of 350 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

VASCage GmbH is the lead sponsor of 12 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients (≥18 years) with a diagnosis of COPD GOLD Group B or E or severe asthma according to current GOLD and GINA recommendations. Participants are recruited from the specialized pulmonary outpatient clinic of the Department of Internal Medicine II, Medical University of Innsbruck, and receive routine clinical care. Patients are followed prospectively to assess cardiovascular comorbidities and their impact on clinical outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18 years or older.
  • Diagnosis of GOLD Group B or E according to current GOLD recommendations, or severe asthma according to current GINA recommendations.
  • Receiving care at the specialized pulmonary outpatient clinic of the Department of Internal Medicine II, Medical University of Innsbruck.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Age below 18 years.
  • Inability or unwillingness to participate in study procedures.
  • Inability or unwillingness to provide written .
  • Planned transfer of care preventing longitudinal follow-up.
  • Pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Interventions

  • OtherRoutine Clinical Care

    Participants receive routine medical care according to local standards of care. No study-specific intervention, treatment allocation, or diagnostic procedure is performed.

06

What researchers measure

Primary outcomes

  1. Prevalence and characterization of cardiovascular comorbidities

    Assessment of the prevalence, type, and distribution of cardiovascular comorbidities in patients with COPD and severe asthma based on clinical, laboratory, and imaging findings obtained during routine care.

    Time frame: Baseline and 24 months

Secondary outcomes

  1. Exacerbation Frequency

    Association between cardiovascular comorbidities and frequency of respiratory exacerbations.

    Time frame: 24 months

  2. Symptom Burden

    Association between cardiovascular comorbidities and respiratory symptom burden as documented in routine clinical assessments.

    Time frame: 24 months

  3. Pulmonary Function

    Association between cardiovascular comorbidities and pulmonary function parameters.

    Time frame: Baseline and 24 months

  4. Treatment Modifications

    Assessment of changes in therapeutic management associated with the identification and characterization of cardiovascular comorbidities.

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2031, 54 months later.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 54 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
May 15, 2031
CompletionEst.
Jun 15, 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Nov 2026
Nov 19, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Nov 19, 2026
    Start date Oct 15, 2026→Nov 2026
  2. Oct 9, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856667
Lead sponsor
VASCage GmbH
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 15, 2031 (estimated)
Completion
Jun 15, 2031 (estimated)
Last update
Nov 19, 2026

Study contacts

Thomas Sonnweber
Contact
thomas.sonnweber@i-med.ac.at
+43 512 504 82586
Tina Pancheri
Contact
tina.pancheri@vascage.at
+43 51255443513
Thomas Sonnweber
principal investigator · Medical University Innsbruck

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion